TScan Therapeutics filed a preliminary proxy statement for a special stockholder meeting scheduled for November 20, 2026. The company seeks approval for a reverse stock split at a ratio ranging from 1-for-2 to 1-for-50. This proposal responds to a Nasdaq deficiency notice regarding the $1.00 minimum bid price requirement.
Separately, board members Garry Nicholson and Gabriela Gruia resigned effective October 13, 2026. TScan confirmed these departures did not result from any disagreements regarding company operations or policies.